RxDoctor Payments Data

Pearl Dy, MD

Endocrinology, Diabetes & Metabolism · Des Moines, IANPI 1134396021

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $340 of the $430 with a category attached, or 79.1%. 12 manufacturers reported payments, led by Abbott at 26.9% of the total. Reporting peaked in 2019 at $203 and has fallen 64.7% since, to $72 in 2024. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in IA, where the typical reported total is $480.

$430in general payments, 2019–2025

Across 16 payments — averaging $26.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$115
  • Amgen$91
  • Medtronic$44
  • Lilly USA, LLC$40
  • Nevro Corp.$26
  • Novo Nordisk$20
  • plus $94 from 6 others

What the payments were for

  • Food & beverage$34079%
  • Education$9021%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$430 in reported general payments places this provider in the 45th percentile of 38 endocrinology, diabetes & metabolism providers in Iowa.

See all endocrinology, diabetes & metabolism providers in Iowa

Medicare billing

Part B allowed, 2024
$38,443
Medicare patients
223
Services billed
643

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide203$248,930
JardianceEmpagliflozin155$139,942
MounjaroTirzepatide94$104,031
TrulicityDulaglutide47$53,845
Tresiba Flextouch U-200Insulin Degludec26$49,319
JanuviaSitagliptin Phosphate47$48,304
RybelsusSemaglutide25$27,296
Fiasp FlextouchInsulin Aspart (Niacinamide)20$21,304
Tresiba Flextouch U-100Insulin Degludec21$19,798
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog33$18,009
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog28$14,383
Humalog Kwikpen U-100Insulin Lispro38$12,856
Novolog FlexpenInsulin Aspart43$11,287
FiaspInsulin Aspart (Niacinamide)13$10,275
Lantus SolostarInsulin Glargine,hum.Rec.Anlog62$9,187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Fiasp$20$286,501241 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$40$163,877183 claims
Boehringer IngelheimJardiance$17$139,942155 claims
Sanofi-aventis U.S. LLCLantus$17$2,63930 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 38 endocrinology, diabetes & metabolism providers in Iowa.

Other endocrinology, diabetes & metabolism in Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →